Mineralys Therapeutics (MLYS)Farallon Capital Management, L.L.C. reduced its stake -850K shares
Farallon Capital Management, L.L.C. reduced its stake in Mineralys Therapeutics, per its Q4 2025 13F.
- 823K
- Shares reported · -850K vs prior quarter
- 0.14%
- Disclosed portfolio weight
- $29.9M
- Reported value
- Holdings as of
- Dec 31, 2025
- Filed
- May 15, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
What came next
- Jun 2, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
- Aug 5, 2026Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results“On August 5, 2026, the Company’s Board of Directors (the Board) appointed James J. Ferguson III, M.D., as the Company’s new Chief Medical Officer, effective August 10, 2026, replacing David Rodman, M.D., who remains with the Company on a full-time basis as a Strategic Advisor.”
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Mineralys Therapeutics
For Mineralys Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MLYS page.
How this filing works
Other disclosures at Mineralys Therapeutics
- SEC Form 4Oct 2, 2026
- SEC Form 4Sep 25, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRMay 15, 2026
Everything OQRO holds on this company is on its MLYS page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
